» Articles » PMID: 32951437

Persistence of Oral Pre-exposure Prophylaxis (PrEP) Among Adolescent Girls and Young Women Initiating PrEP for HIV Prevention in Kenya

Abstract

The Determined, Resilient, Empowered, AIDS-free, Mentored, and Safe (DREAMS) Initiative aims to reduce HIV infections among adolescent girls and young women (AGYW) in Africa. Oral pre-exposure prophylaxis (PrEP) is offered through DREAMS in Kenya to eligible AGYW in high burden counties including Kisumu and Homa Bay. This study examines PrEP persistence among AGYW in high burden community-based PrEP delivery settings. We evaluated PrEP persistence among AGYW in the DREAMS PrEP program in Kisumu and Homa Bay using survival analysis and programmatic PrEP refill data collected between March through December 2017. Among 1,259 AGYW who initiated PrEP during the study period, the median persistence time in the program was 56 days (95% CI: 49-58 days) and the proportion who persisted 3 months later was 37% (95% CI: 34-40%). Persistence varied by county ( < 0.001), age at PrEP initiation ( = 0.002), marital status ( = 0.008), transactional sex ( = 0.002), gender-based violence (GBV) experience ( = 0.009) and current school attendance ( = 0.001) at DREAMS enrollment. Persistence did not vary with orphan status, food insecurity, condom use, age at first sexual encounter or engagement in age-disparate sex at DREAMS enrollment. Targeted strategies are needed to improve AGYW retention in the PrEP program.

Citing Articles

Pre-exposure prophylaxis access, uptake and usage by young people: a systematic review of barriers and facilitators.

Warzywoda S, Fowler J, Dyda A, Fitzgerald L, Mullens A, Dean J Ther Adv Infect Dis. 2024; 11:20499361241303415.

PMID: 39650691 PMC: 11624559. DOI: 10.1177/20499361241303415.


Alignment of PrEP Use With Potential HIV Exposure in Young Women and Men in Uganda.

Wu L, Ssebuliba T, Muwonge T, Bambia F, Stein G, Nampewo O J Acquir Immune Defic Syndr. 2024; 98(4):326-333.

PMID: 39630076 PMC: 11841727. DOI: 10.1097/QAI.0000000000003573.


Pre-exposure prophylaxis implementation gaps among people vulnerable to HIV acquisition: a cross-sectional analysis in two communities in western Kenya, 2021-2023.

Romo M, Schluck G, Kosgei J, Akoth C, Bor R, Langat D J Int AIDS Soc. 2024; 27(11):e26372.

PMID: 39496511 PMC: 11534481. DOI: 10.1002/jia2.26372.


Preferences for Delivery of HIV Prevention Services Among Healthcare Users in South Africa: A Discrete Choice Experiment.

Martin C, Blaauw D, Nongena P, Chidumwa G, Dada S, Jack S AIDS Behav. 2024; 29(1):331-341.

PMID: 39349906 PMC: 11739183. DOI: 10.1007/s10461-024-04519-4.


"I was given PrEP, but had no privacy": Mystery shopper perspectives of PrEP counseling for adolescent girls and young women in Kisumu County, Kenya.

Vera M, Aketch H, Omom C, Otieno F, Owiti G, Sila J PLoS One. 2024; 19(8):e0309075.

PMID: 39159171 PMC: 11332929. DOI: 10.1371/journal.pone.0309075.


References
1.
Thigpen M, Kebaabetswe P, Paxton L, Smith D, Rose C, Segolodi T . Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012; 367(5):423-34. DOI: 10.1056/NEJMoa1110711. View

2.
Klop C, Welsing P, Elders P, Overbeek J, Souverein P, Burden A . Long-term persistence with anti-osteoporosis drugs after fracture. Osteoporos Int. 2015; 26(6):1831-40. PMC: 4469296. DOI: 10.1007/s00198-015-3084-3. View

3.
Patterson K, Prince H, Kraft E, Jenkins A, Shaheen N, Rooney J . Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med. 2011; 3(112):112re4. PMC: 3483088. DOI: 10.1126/scitranslmed.3003174. View

4.
Nakku-Joloba E, Pisarski E, Wyatt M, Muwonge T, Asiimwe S, Celum C . Beyond HIV prevention: everyday life priorities and demand for PrEP among Ugandan HIV serodiscordant couples. J Int AIDS Soc. 2019; 22(1):e25225. PMC: 6338102. DOI: 10.1002/jia2.25225. View

5.
Celum C, Delany-Moretlwe S, Baeten J, van der Straten A, Hosek S, Bukusi E . HIV pre-exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to delivery. J Int AIDS Soc. 2019; 22 Suppl 4:e25298. PMC: 6643076. DOI: 10.1002/jia2.25298. View